Dubermatinib tartrate is under clinical development by Sumitomo Dainippon Pharma Oncology and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Dubermatinib tartrate’s likelihood of approval (LoA) and phase transition for Colorectal Cancer took place on 05 Nov 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

In addition, the same event on 05 Nov 2021 decreased Dubermatinib tartrate’s LoA and PTSR for Melanoma, and decreased LoA and PTSR for Ovarian Cancer.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Dubermatinib tartrate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Dubermatinib tartrate overview

Dubermatinib tartrate (TP-0903, HCI-2084) is under development for the treatment of solid tumors including non-small cell lung cancer, colorectal cancer, melanoma, ovarian cancer, breast cancer, head and neck cancer, hematological tumors including acute myeloid leukemia, T-cell acute lymphoblastic leukemia (T-ALL), and acute myelocytic leukemia. It is a small molecule administered orally. The drug candidate acts by targeting Axl Kinase. It was also under development for the treatment of chronic lymphocytic leukemia.

Sumitomo Dainippon Pharma Oncology overview

Sumitomo Dainippon Pharma Oncology (Sumitomo Dainippon), formerly Boston Biomedical, a subsidiary of Sumitomo Chemical Co Ltd, is a developer of novel therapeutics to treat cancer. The company offers drug discovery, crystallography, medicinal chemistry, preclinical development, pharmacology, pharmaceutical development, clinical trials, and regulatory affair services. Its drug candidates include BBI608 and BBI503. The company also offers cancer stem cell development programs that include cancer cell stemless, signaling pathways, treatment resistance, recurrence and metastasis; resources and CSC programs. Sumitomo Dainippon is headquartered in Cambridge, Massachusetts, the US.

Quick View Dubermatinib tartrate LOA Data

Report Segments
  • Innovator
Drug Name
  • Dubermatinib tartrate
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: Sumitomo Dainippon Pharma Oncology
  • Originator: University of Utah
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.